Predictors of recurrence following an initial episode of transverse myelitis
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: This study sought to identify factors that increased the risk of recurrence after an initial transverse myelitis (TM) presentation.
Methods: Retrospective cohort study of 192 patients initially presenting with TM of unknown etiology. Patients diagnosed with multiple sclerosis during the first myelitis episode were excluded. Demographic and laboratory data were analyzed for associations with recurrence.
Results: One hundred ten of 192 patients (57%) eventually developed recurrent symptoms: 69 (63%) neuromyelitis optica (NMO) or NMO spectrum disorder, 34 (31%) non-NMO recurrent TM, and 7 (6%) systemic autoimmune disease. Multiple independent risk factors for recurrence were identified: African American race (risk ratio 1.60, p < 0.001, 95% confidence interval 1.26–2.03; similarly noted hereafter), female sex (1.88, p = 0.007, 1.19–2.98), longitudinally extensive myelitis at onset (1.34, p = 0.036, 1.01–1.78), Sjogren syndrome antigen A (1.89, p = 0.003, 1.44–2.48), vitamin D insufficiency (4.00, p < 0.001, 1.60–10.0), antinuclear antibody titer ≥1:160 (1.69, p = 0.006, 1.23–2.32), and the presence of inflammatory markers (e.g., immunoglobulin G index) in the CSF (2.14, p < 0.001, 1.44–3.17).
Conclusions: Sex, race, and serologic biomarkers warrant consideration when assessing risk of TM recurrence. Male sex and Caucasian American race were independently associated with risk of monophasic idiopathic TM. Recurrence risk in female and African American patients appears driven by a greater likelihood of developing NMO or NMO spectrum disorder.
GLOSSARY
- ANA=
- antinuclear antibody;
- Ig=
- immunoglobulin;
- JHH=
- Johns Hopkins Hospital;
- LETM=
- longitudinally extensive TM;
- MAD=
- median absolute deviation;
- MS=
- multiple sclerosis;
- NMO=
- neuromyelitis optica;
- NMOSD=
- NMO spectrum disorder;
- OR=
- odds ratio;
- SLE=
- systemic lupus erythematosus;
- TM=
- transverse myelitis
Footnotes
Go to Neurology.org/nn for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the authors.
- Received March 11, 2014.
- Accepted in final form March 17, 2014.
- © 2014 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
- Impact of Vitamin D in Recurrent Transverse Myelitis
- Michael Levy, Assistant Professor, Johns Hopkins University[email protected]
- Maureen A. Mealy, Baltimore, MD; Dorlan J. Kimbrough, Baltimore, MD; Alexandra Simpson, Baltimore, MD
Submitted July 01, 2014 - Is there any role of serum Parathyroid hormone as a risk factors for recurrent transeverse myelitis
- Rameshwar N. Chaurasia, Associate Professor Neurology, Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, varanasi-221005[email protected]
Submitted June 25, 2014 - Response from the authors
- Michael Levy, Assistant Professor, Johns Hopkins University[email protected]
- Dorlan Kimbrough, Baltimore, MD; Maureen Mealy, Baltimore, MD; Alexandra Simpson, Baltimore, MD
Submitted May 26, 2014 - Predictors of recurrence of transverse myelitis: role of evoked potentials
- Nitin K. Sethi, Assistant Professor of Neurology, New York-Presbyterian Hospital, Weill Cornell Medical Center, 525 East 68th Street, New York, NY 100[email protected]
- Nitin K Sethi, New York, NY
Submitted May 24, 2014 - SUBMIT YOUR LETTER NOW TO NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION!
- NONE NONE, [email protected]
Submitted April 24, 2014
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Views & Reviews
International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al.Neurology, June 19, 2015 -
Articles
A population-based study of neuromyelitis optica in CaucasiansN. Asgari, S.T. Lillevang, H.P.B. Skejoe et al.Neurology, May 02, 2011 -
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Resident and Fellow Section
Clinical Reasoning: A patient with a history of encephalomyelitis and recurrent optic neuritisJosef Maxwell Gutman, Michael Levy, Steven Galetta et al.Neurology, November 06, 2017